創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/01/07 GEM061 Curcumin-releasing topical formulation (sustained release for about 24 hours) Please refer to Note Topical Small molecule
Preclinical Indication:
Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell)

Note:
Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes.
This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model.
問合せ
19/01/07 GEM060 Nitric Oxide-releasing topical formulation (sustained release for over 48 hours) Please refer to Note Topical Small molecule
Preclinical Indication:
Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others

Note:
NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc.
Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers.
This formulation breaks through the limitations of sustained NO (topical) delivery.
問合せ
18/12/27 GEM059 Recombinant Human Interleukin-1 Receptor Antagonist Please refer to Note IM Protein
Phase 1 Indication:
1: Infection, as manifested by febrile neutropenia, in patients with malignancies receiving chemotherapy drugs.
2: Diarrhea in patients with malignancies receiving chemotherapy drugs.
3. Gout arthritis

Note:
The world's first multiorgan protection agent for tumor chemotherapy.
Inhibits cell cycle progression of normal cells and renders them resistanace to chemotherapy.
No effects on tumor growth and their sensitivity to chemotherapy
Phase 1 : No dose limiting toxicity, None of subjects presented grade 3 or above chemotherapy-induced neutropenia or diarrhea.
Gout arthritis: Well tolerated and safe for patients who are restricted from NSAID, glucocorticoid, or colchicine.
問合せ
18/12/27 GEM058 Increase cellular ATP and promote wound healing Diabetes foot ulcer Topical Small molecule
Phase 2 Reducing inflammation of endothelial cells of blood vessels.
Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent.
Applicable to all kind of wound and low cost treatment
Phase 2: The estimated complete closure rate is around 60% (vs placebo 30%)
問合せ
18/12/27 GEM057 Increase hair follicle ATP and delay senescence of dermal papilla cells Alopecia Topical Small molecule
Phase 2 Boosts the ATP of human follicle dermal papilla cells, thereby slowing down the aging speed and prolonging hair cycle.
No side effects and shorter time to observe efficacy
Human trial (Androgenetic Alopecia): significantly improved 37.5% vs 0% (placebo) during 2 months
Phase 2 (Female pattern hair loss) : ongoing (comparison with minoxidil)
問合せ
18/12/20 GEM056 Novel PDL1/CDx bispecific antibody Cancer with T cell inactivation and CDC inactivation Injection Protein
Preclinical First bispecific combining the following two mechanisms: 1) Release cancer repression on T cell activation not only by blocking PDL1/PD1 interaction, but also by inducing PDL1 internalization into cancer cells; 2) Release cancer repression on CDC by downregulation of CDC repressor overexpressed by cancer cells (CDx is a CDC repressor overexpressed by multiple cancers, this bispecific can induce CDx internalization on cancer cells). 問合せ
18/12/20 GEM055 Novel CD20/CD3 bispecific antibody Rituxan resistant cancer Infusion Protein
Preclinical Unique features by computational designed bispecific antibody:
1) Better safety to reduce CDR: T cell activation and T cell killing are only detected in the presence of target cancer cell
2) Multiple MOA to target cancer heterogeneity: Extremely low CD3 binding enables “safe maintenance" of ADCC/CDC in addition to T cell killing. This BsAb can delay cancer relapse compared to Rituximab
3) Better developability : More than 95% of heterodimer formation due to novel Fc mutations on top of a pair of "knob into hole", designed biochemical and biophysical difference between the two arms enables easier purification.
問合せ
18/12/13 GEM054 Intracellular superoxide removing agent Please refer to Note IV Small molecule
Phase 2 Indication: Chemotherapy induced Peripheral Neuropathy (CIPN)

Note: There is currently no approved drug to prevent or treat CIPN.
Completion of Phase 2b study.
Global Phase 3 started in US, Currently in preparation for Phase 3 in Japan, South Korea, Taiwan and Hong Kong.
Can be licensed to Japan, South Korea, Taiwan and Hong Kong.
問合せ
18/12/13 GEM053 Substance for covering oral lesions (no active ingredients: medical device) Control and relief pain of oral mucositis by chemotherapy/ radiotherapy Local Small molecule
Launch There is no standard treatment for chemo/radiotherapy induced mucositis–high unmet medical needs.
Forms a mucoadhesive barrier film when applied in the oral cavity. Excellent control of oral pain (rapid and long-lasting effects and ready to use)
Can be licensed to Korea.
問合せ
18/12/13 GEM052 Mitochondria-targeted apoptosis inducer Please refer to Note IV Small molecule
Phase 2 Indication: Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) and other hematological cancers

Note: No approved drugs for PTCL indication in Europe (3 drugs have been approved in Japan and US).
Less toxic compared with competitors approved in Japan and US.
US Phase 2a: 5 responders in 11 refractory PTCL and DLBCL patients, and 2 responders in 7 PTCL patients. Applicable to relapsed and refractory PTCL.
Phase 2 Pan-Asia pivotal study is ongoing.
Can be licensed to US/EU and China (except Beijing, Shanghai, and Guangzhou).
問合せ